Durham-based medical dermatology company, Novan, Inc., is actively focused on developing and commercializing therapeutic products to combat various skin diseases. With a range of clinical stage dermatology drug candidates including SB204 for treating acne vulgaris, SB206 for viral skin infections, SB208 for fungal infections of the skin and nails, and SB414 for inflammatory skin diseases, the company is pioneering treatments for a wide variety of conditions. Additionally, Novan is developing other product candidates such as SB207, for the treatment of external genital warts, WH602, a nitric oxide-containing intravaginal gel to combat high-risk human papilloma virus (HPV), WH504, a non-gel HPV treatment candidate, and SB019 for the highly topical COVID-19. Novan has solidified its position in the industry through licensing agreements with Sato Pharmaceutical Co., Ltd. as well as a strategic alliance with Orion Corporation. The company was established in 2006 and has since remained at the forefront of innovation in the medical dermatology field.